Because ERK lies downstream of KRAS, EGFR cannot induce permanent inhibition in pancreatic cancer, but MEK1/2 inhibitors, which target downstream of KRAS and upstream of ERK, have been approved by the FDA for BRAF mutated melanoma and are being tested in many other cancers. The gene discussed is KRAS; the disease is pancreatic neoplasm.